title: Effectiveness of nebulized N-acetylcysteine solution in children with acute bronchiolitis.
abstract: OBJECTIVE
  To evaluate the effectiveness of nebulized mucolytic therapy (N-acetylcysteine) in treatment of children with acute bronchiolitis.
  
  
  METHODS
  Prospective randomized, controlled study.
  
  
  METHODS
  Paediatric Medical Unit of the Children's Hospital and the Institute of Child Health, Lahore, from November 2011 to April 2012.
  
  
  METHODS
  All the patients aged 2 months to 24 months, with the diagnosis of acute viral bronchiolitis were enrolled in the study. A predesigned proforma was completed after taking parental consent. All eligible patients were randomly assigned to one of the two groups: group-1 received N-acetylcysteine in nebulized form, and group-2 received salbutamol as a nebulized aerosol. Both groups were then compared regarding their clinical improvement and duration of stay in the hospital. The data obtained was analyzed on the statistical software SPSS version 16. Descriptive statistics were obtained by frequencies and percentages. Chi-square test was applied to find p-value.
  
  
  RESULTS
  A total of 100 patients met the inclusion criteria. The mean age was 3 months. On the first day of treatment, the mean clinical severity score at baseline were 5.38 ± 2.62 in group-1 and 4.68 ± 2.2 in group-2. At day 3 and 5, it was 2.9 ± 1.48 and 3.30 ± 1.77 in group-1 and 0.88 ± 1.08 and 1.90 ± 1.32 in group-2 respectively. The clinical severity score after N-acetylcysteine inhalation therapy was better in group-1 on the third but more so on fifth day after hospital admission. The mean duration of hospitalization was 4.67 ± 2.2 days for the whole population and it differed between the 2 groups: 4.36 ± 1.66 days in group-1 versus 4.98 ± 2.6 days in group-2.
  
  
  CONCLUSIONS
  On the basis of improvement in clinical severity score and early discharge from the hospital, N-acetylcysteine was found to be an effective therapy in acute bronchiolitis.
authors: Department of Paediatric Medicine, The Children's Hospital and Institute of Child Health, Lahore.
authors: Farrah
authors: F
authors: Naz
authors: Department of Paediatric Medicine, The Children's Hospital and Institute of Child Health, Lahore.
authors: Afsheen Batool
authors: AB
authors: Raza
authors: Department of Paediatric Medicine, The Children's Hospital and Institute of Child Health, Lahore.
authors: Iftikhar
authors: I
authors: Ijaz
authors: Department of Paediatric Medicine, The Children's Hospital and Institute of Child Health, Lahore.
authors: Muhammad Yaqoob
authors: MY
authors: Kazi
mesh_terms: D000111:Acetylcysteine / Q000008:administration & dosage* / Q000009:adverse effects; D000208:Acute Disease; D000280:Administration, Inhalation; D000420:Albuterol / Q000008:administration & dosage* / Q000009:adverse effects; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001990:Bronchiolitis, Viral / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D006760:Hospitalization; D006801:Humans; D007223:Infant; D008297:Male; D009330:Nebulizers and Vaporizers; D011446:Prospective Studies; D018357:Respiratory Syncytial Virus Infections / Q000150:complications / Q000188:drug therapy; D012136:Respiratory Syncytial Viruses / Q000302:isolation & purification; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D001993:Bronchodilator Agents; D000420:Albuterol; D000111:Acetylcysteine